Pulmonary hypertension associated with congenital diaphragmatic hernia is still one
of the major challenges in neonatal intensive care units. Several relevant pathways
in its pathogenesis have been described and studied, but the absence of well-designed
randomized controlled trials and the scattered data on the pharmacokinetics and pharmacodynamics
of most of the drugs used in these patients hamper progress significantly. This review
aims to give an overview of current management strategies in the antenatal and neonatal
phase, and provides founded clinical recommendations.
Keywords
congenital diaphragmatic hernia - pulmonary hypertension - neonates - NO pathway